Hypoxia-inducible factor-2α regulates the expression of TRAIL receptor DR5 in renal cancer cells

Carcinogenesis

Volumn 29, Issue 9, 2008, Pages 1734-1741

  Mahajan, S ^a   Dammai, V ^a,b   Hsu, T ^a,b   Kraft, A S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEATH RECEPTOR 5; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LUCIFERASE; MAX PROTEIN; MESSENGER RNA; MYC PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; WILD TYPE;

APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; LUCIFERASES; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 51849106844     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn132     Document Type: Article

References (48)

1. Jemal,A. et al. (2003) Cancer statistics, 2003. CA Cancer J. Clin., 53, 5-26.
2. Stadler,W.M. (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer, 104, 2323-2333.
3. Staehler,M. et al. (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets, 6, 835-846.
4. Griffith,T.S. et al. (2002) Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res., 62, 3093-3099.
5. Pitti,R.M. et al. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271, 12687-12690.
6. Wiley,S.R. et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-682.
7. Walczak,H. et al. (2000) The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res., 256, 58-66.
8. Pan,G. et al. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815-818.
9. Sheridan,J.P. et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-821.
10. Zeng,Y. et al. (2006) Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int. J. Oncol., 28, 421-430.
11. Zhang,L. et al. (2007) Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett., 251 146-157.
12. Johnson,T.R. et al. (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negatiV6-or Bcl-xL overexpressing cells. Oncogene, 22, 4953-4963.
13. Nikrad,M. et al. (2005) The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther., 4, 443-449.
14. Qin,J.Z. et al. (2006) Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res., 66, 9636-9645.
15. Zhu,H. et al. (2005) Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol. Ther., 4, 781-786.
16. Gnarra,J.R. et al. (1994) Mutations of the, VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7, 85-90.
17. Tsutsumi,H. et al. (2003) VHL tumor suppressor gene: Its mutation and protein level in renal cell carcinoma. Oncol. Rep., 10, 1357-1361.
18. Wilhelm,M. et al. (1995) Terminal deletion of chromosome 3p sequences in nonpapillary renal cell carcinomas: A breakpoint cluster between loci D3S1285 and D3S1603. Cancer Res., 55, 5383-5385.
19. Ivan,M. et al. (2001) The von Hippel-Lindau tumor suppressor protein. Curr Opin. Genet. Dev., 11, 27-34.
20. Maynard,M.A. et al. (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem., 278, 11032-11040.
21. Ohh,M. et al. (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell, 1, 959-968.
22. Hergovich,A. et al. (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 5, 64-70.
23. Hsu,T. et al. (2006) Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J. Biol. Chem., 281, 12069-12080.
24. Kamada,M. et al. (2001) von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res., 61, 4184-4189.
25. Pioli,P.A. et al. (2001) The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J. Biol. Chem., 276, 40346-40352.
26. Kroll,S.L. et al. (1999) von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells. J. Biol. Chem., 274, 30109-30114.
27. Qi,H. et al. (2003) The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res., 63, 7076-7080.
28. Kallio,P.J. et al. (1999) Regulation of the hypoxia-inducible transcription factor lalpha by the ubiquitin-proteasome pathway. J. Biol. Chem., 274, 6519-6525.
29. Na,X. et al. (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol., 170, 588-592.
30. Zatyka,M. et al. (2002) Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res., 62, 3803-3811.
31. Raval,R.R. et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol., 25, 5675-5686.
32. Perazzi,B. et al. (2006) The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc. Natl Acad. Sci. USA, 103, 14531-14536.
33. Gordan,J.D. et al. (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell, 11, 335-347.
34. Zhang,H. et al. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 11, 407-420.
35. Yoshida T. et al. (2005) Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res., 65, 5662-5667.
36. Kim,M. et al. (1998) Recombinant adenovirus expressing von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kipl. Biochem. Biophys. Res. Commun., 253, 672-677.
37. Roe,J.S. et al. (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell, 22, 395-405.
38. Cui,H. et al. (2005) Linking of N-Myc to death receptor machinery in neuroblastoma cells. J. Biol. Chem., 280, 9474-9481.
39. Wang,Y. et al. (2004) Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell, 5 501-512.
40. Davis,N.B. et al. (2004) Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J. Clin. Oncol., 22, 115-119.
41. Kondagunta,G.V et al. (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol., 22, 3720-3725.
42. Koshiji,M. et al. (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J., 23, 1949-1956.
43. Covello,K.L. et al. (2005) Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res., 65, 2277-2286.
44. Hu,C.J. et al. (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol., 23, 9361-9374.
45. Kim,J.W. et al. (2007) HIF-1 and dysregulated c-Myc cooperatively induces VEGF and metabolic switches, HK2 and PDK1. Mol. Cell. Biol. 27, 7381-7393.
46. Nieminen,A.I. et al. (2007) c-Myc primed njitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J., 26 1055-1067.
47. Ricci,M.S. et al. (2007) Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL induced death. Cancer Cell, 12, 66-80.
48. Gordan,J.D. et al. (2007) HIF and c-Myc: Sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell, 12, 108-113.